Physician profile
Sameer K Mathur
NPI 1063488138
$257,595.07
in general payments reported to CMS, 2019-2025
10 companies · $26K in 2025
The $26K reported for 2025 was more than what 93% of Pediatric Allergy/Immunology providers received nationally (typical 2025 total: $375).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $42K · 2020: $42K · 2021: $67K · 2022: $21K · 2023: $41K · 2024: $17K · 2025: $26K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $69K · Travel and Lodging: $7,428 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,800 · Food and Beverage: $2,559 · Education: $53.31.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $68,828.58 |
| Travel and Lodging | $7,427.95 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,800.00 |
| Food and Beverage | $2,559.49 |
| Education | $53.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $84,927.41 | 2019-2025 | Airsupra, Fasenra, Tezspire |
| Glaxosmithkline, LLC. | $63,157.25 | 2020-2025 | Nucala |
| Astrazeneca Uk Limited | $37,332.40 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $24,285.00 | 2023-2025 | |
| Astrazeneca Ab | $22,462.71 | 2021-2023 | Fasenra |
| Genzyme Corporation | $11,424.22 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $8,319.39 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $4,001.25 | 2021-2024 | Dupixent |
| Alk-Abello, INC | $1,651.44 | 2021 | |
| Amgen INC. | $34.00 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sameer Mathur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.